Recombinant human deoxyribonuclease improves atelectasis in mechanically ventilated children with cardiac disease

Area of Science:

• Pediatric critical care medicine
• Respiratory therapy
• Pharmacology

Background:

• Atelectasis is a common complication in mechanically ventilated children with cardiac disease.
• Current treatments for atelectasis in this population have limitations.
• Recombinant human deoxyribonuclease (rhDNase) is a mucolytic agent with potential therapeutic benefits.

Purpose of the Study:

• To evaluate the efficacy and safety of rhDNase in improving atelectasis in pediatric cardiac patients requiring mechanical ventilation.
• To identify patient subgroups that may benefit most from rhDNase therapy.

Main Methods:

• Retrospective cohort study of pediatric patients receiving short-term rhDNase therapy for atelectasis.
• Analysis of patient characteristics, gas exchange, ventilatory parameters, and chest radiographs.
• Investigation of rhDNase effectiveness based on pre-treatment tracheal aspirate findings (neutrophils, bacteria).

Main Results:

• rhDNase significantly improved atelectasis on chest radiographs without major changes in gas exchange or ventilatory parameters.
• The therapeutic effect was most pronounced within 10 doses.
• rhDNase was more effective in patients with moderate to high amounts of neutrophils and/or bacteria in tracheal aspirates (P < 0.007).
• No adverse effects were reported.

Conclusions:

• rhDNase is a safe and effective treatment for atelectasis in mechanically ventilated children with cardiac disease.
• The presence of moderate neutrophils and/or bacteria in tracheal aspirates predicts a better response to rhDNase therapy.
• rhDNase offers a valuable therapeutic option for managing atelectasis in this vulnerable patient group.